Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
05/06/2023 16:17
June 5 (Reuters) - CohBar Inc CWBR.O :
* MORPHOGENESIS, INC. AND COHBAR, INC. ANNOUNCE POSITIVE
RESULTS
FROM PHASE 1B TRIAL OF IFX-HU2.0, A NOVEL PERSONALIZED CANCER
VACCINE, IN CHECKPOINT INHIBITOR RESISTANT ADVANCED MERKEL CELL
CARCINOMA (MCC) AND CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
Source text for Eikon: ID:nGNX7VF4rz
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma